tbuckley/cabot-search huggingface dataset:
Gene correlation network analysis to identify regulatory factors in idiopathic pulmonary fibrosis
Authors: John E McDonough, Naftali Kaminski, Bernard Thienpont, James C Hogg, Bart M Vanaudenaerde, Wim A Wuyts
Journal: Thorax (2018)

Background Idiopathic pulmonary fibrosis (IPF) is a severe lung disease characterised by extensive pathological changes. The objective for this study was to identify the gene network and regulators underlying disease pathology in IPF and its association with lung function. Methods Lung Tissue Research Consortium dataset with 262 IPF and control subjects (GSE47460) was randomly divided into two non-overlapping groups for cross-validated differential gene expression analysis. Consensus weighted gene coexpression network analysis identified overlapping coexpressed gene modules between both IPF groups. Modules were correlated with lung function (diffusion capacity, DL CO ; forced expiratory volume in 1 s, FEV 1 ; forced vital capacity, FVC) and enrichment analyses used to identify biological function and transcription factors. Module correlation with miRNA data (GSE72967) identified associated regulators. Clinical relevance in IPF was assessed in a peripheral blood gene expression dataset (GSE93606) to identify modules related to survival. Results Correlation network analysis identified 16 modules in IPF. Upregulated modules were associated with cilia, DNA replication and repair, contractile fibres, B-cell and unfolded protein response, and extracellular matrix. Downregulated modules were associated with blood vessels, T-cell and interferon responses, leucocyte activation and degranulation, surfactant metabolism, and cellular metabolic and catabolic processes. Lung function correlated with nine modules (eight with DL CO , five with FVC). Intermodular network of transcription factors and miRNA showed clustering of fibrosis, immune response and contractile modules. The cilia-associated module was able to predict survival (p=0.0097) in an independent peripheral blood IPF cohort. Conclusions We identified a correlation gene expression network with associated regulators in IPF that provides novel insight into the pathological process of this disease.
Interim results from exploratory study to determine S-588410-induced tumor infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients
Authors: T. Kojima, T. Marafioti, T. Fujiwara, Y. Shirakawa, T. Nakatsura, K. Kato, I. Puccio, M. Nagira, N. Ide, K. Stoeber, A. Arimura, H. Daiko
Journal: Annals of Oncology (2018)
Evaluation of clinicopathological and molecular criterias for screening of exonucleasic domain POLE (edPOLE) mutated patients in proficient mismatch repair (pMMR) colorectal and endometrial cancers
Authors: J. Cohen, B.J.-C. Rousseau, R. Bourgoin, C. Tournigand, L. Larnaudie, A. Dupuy, M. Ollier, A. Pujals
Journal: Annals of Oncology (2018)
Phase I trial of a novel hTERT vaccination strategy addressing T effector cells and immune-suppressor mechanisms
Authors: J. Spicer, V. Kwatra, C. Verma, K. Ioannou, R. Goldstein, T. Brier, J. Eremin, N. Zareian, L. Walker, D. Lobo, F. Farzaneh, O. Eremin
Journal: Annals of Oncology (2018)
Prognostic value of neutrophil-lymphocite ratio in resected high risk colorectal cancer: An analysis of adjuvant TOSCA trial
Authors: F. Petrelli, G. Rosati, M. Banzi, M.G. Zampino, N. Pella, M. Di Bartolomeo, E. Maiello, P. Bidoli, D. Ferrari, L. Rimassa, R. Labianca, M. Scartozzi, S. Lonardi, S. de Placido, A. Zaniboni, A. Sobrero, L.G. Frassineti, N. Silvestris, D. Corsi, F. Galli, S. Barni
Journal: Annals of Oncology (2018)
The HOBOE-2 multicenter randomized phase III trial in premenopausal patients with hormone-receptor positive early breast cancer comparing triptorelin plus either tamoxifen or letrozole or letrozole + zoledronic acid
Authors: F. Perrone, M. De Laurentiis, S. de Placido, M. Orditura, S. Cinieri, F. Riccardi, A.S. Ribecco, C. Putzu, L. Del Mastro, E. Rossi, B. Daniele, A.M. Mosconi, F. Di Rella, G. Landi, F. Nuzzo, C. Pacilio, R. Lauria, L. Arenare, M.C. Piccirillo, C. Gallo
Journal: Annals of Oncology (2018)
Poverty and outcomes of people with severe mental disorders in rural China: a 21-year survey
Authors: Mao-Sheng Ran, Yue-Hui Yu, Man-Man Peng, Yu-Jun Liu, Tian-Ming Zhang, Shi-Hui Hu, Die Zhou, Hai-Jun Yang, Xin Yang, Wei Luo, Chang-Cheng Liu, Bo Liu, Ke-Zhi Liu, Ke Gong, Chao-Hua Huang, Tin Zhang, Yong-You Yao, Cecilia Lai-Wan Chan, Meng-Ze Xiang
Journal: The Lancet (2018)
Incidence of cardiac toxicities in patients with advanced non-small cell lung cancer treated with osimertinib: A combined analysis of two phase III randomized controlled trials
Authors: K.Z. Thein, S. Swarup, S. Ball, M. Quirch, Y. Vorakunthada, K.K. Htwe, N. D'Cunha, F. Hardwicke, S. Awasthi, L. Tijani
Journal: Annals of Oncology (2018)
P1.01-112 Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC
Authors: C. Zhou, Y. Cheng, Y. He, W. Li, H. Zhang, Q. Zhou, B. Wang, C. Liu, S. Ramalingam, A. Walding, M. Saggese, J. Wang, M. Fan, Y. Wu
Journal: Journal of Thoracic Oncology (2018)
OA09.03 Discussions Between Health Professionals and Smokers About E-Cigarettes: Results from the ITC Policy Evaluation Project
Authors: S. Gravely, J. Thrasher, K.M. Cummings, J. Ouimet, A. Mcneill, G. Meng, E.N. Lindblom, R. Loewen, R. O’Connor, M.E. Thompson, S.C. Hitchman, D. Hammond, B.W. Heckman, R. Borland, H. Yong, T. Elton-Marshall, M. Bansal Travers, C. Gartner, G. Fong
Journal: Journal of Thoracic Oncology (2018)
Pathology and Pathogenesis of Chagas Heart Disease
Authors: Kevin M. Bonney, Daniel J. Luthringer, Stacey A. Kim, Nisha J. Garg, David M. Engman
Journal: Annual Review of Pathology Mechanisms of Disease (2018)

Chagas heart disease is an inflammatory cardiomyopathy that develops in approximately one-third of people infected with the protozoan parasite Trypanosoma cruzi. One way T. cruzi is transmitted to people is through contact with infected kissing bugs, which are found in much of the Western Hemisphere, including in vast areas of the United States. The epidemiology of T. cruzi and Chagas heart disease and the varied mechanisms leading to myocyte destruction, mononuclear cell infiltration, fibrosis, and edema in the heart have been extensively studied by hundreds of scientists for more than 100 years. Despite this wealth of knowledge, it is still impossible to predict what will happen in an individual infected with T. cruzi because of the tremendous variability in clonal parasite virulence and human susceptibility to infection and the lack of definitive molecular predictors of outcome from either side of the host-parasite equation. Further, while several distinct mechanisms of pathogenesis have been studied in isolation, it is certain that multiple coincident mechanisms combine to determine the ultimate outcome. For these reasons, Chagas disease is best considered a collection of related but distinct illnesses. This review highlights the pathology and pathogenesis of the most common adverse sequela of T. cruzi infection-Chagas heart disease-and concludes with a discussion of key unanswered questions and a view to the future.
P2.01-57 Prognostic Implication of Clinical, Imaging, and Pathologic Parameters in N2(+) Stage IIIA Lung Cancer Patients
Authors: H. Kim, Y.C. Ahn, J.M. Kim, H. Pyo, J.M. Noh, J. Sun, J.S. Ahn, M. Ahn, K. Park, Y.S. Choi, J. Kim, J.I. Zo, Y.M. Shim, J. Han, S.H. Hyun, J.Y. Choi
Journal: Journal of Thoracic Oncology (2018)
Dynamic monitoring of KRAS, NRAS, BRAF and PIK3CA mutations in circulating cell-free DNA for metastatic colorectal cancer patients treated with cetuximab
Authors: L.L. Liu, Z. Tong, C. Yan, H. Zhang, W. Jiang, Y. Zheng, P. Zhao, W. Fang
Journal: Annals of Oncology (2018)
P1.01-32 A Multicenter, Open-Label, Phase II Trial of S-1 Plus Carboplatin in Advanced Non-Small Cell Lung Cancer Patients with Interstitial Lung Disease
Authors: M. Hanibuchi, S. Kakiuchi, S. Atagi, F. Ogushi, E. Shimizu, T. Haku, Y. Toyoda, M. Azuma, M. Kondo, H. Kawano, K. Otsuka, S. Sakaguchi, H. Nokihara, H. Goto, Y. Nishioka
Journal: Journal of Thoracic Oncology (2018)
A noninferiority trial of cabozantinib (C) comparing 60 mg vs 140 mg orally per day to evaluate the efficacy and safety in patients (pts) with progressive, metastatic medullary thyroid cancer (MTC)
Authors: J. Krajewska, B.G. Robinson, B. Keam, J. Capdevila, A. Klochikhin, H. Gan, E. Kapiteijn, R. Elisei, J. Partyka, A.E. Borgman, M. Schlumberger
Journal: Annals of Oncology (2018)
P1.01-113 Analysis of Clinicopathological Features and Clinical Efficacy of Crizotinib in ROS1 Positive Non-Small Cell Lung Cancer
Authors: Y. Zhu, X. Li, L. Wu, H. Chen, W. Wang, C. Xu, M. Fang, J. Shen, K. Du, W. Zhuang, Y. Chen, G. Chen
Journal: Journal of Thoracic Oncology (2018)
P3.12-16 Prognostic Impact of M Descriptors of the 8th Edition of TNM Classification for Extensive Disease-Small Cell Lung Cancer
Authors: M. Shirasawa, T. Fukui, S. Kusuhara, Y. Hiyoshi, M. Ishihara, M. Kasajima, N. Nishinarita, S. Harada, S. Igawa, M. Yokoba, H. Mitufuji, M. Kubota, M. Katagiri, J. Sasaki, K. Naoki
Journal: Journal of Thoracic Oncology (2018)
Starvation in the Midst of Plenty: Reflections on the History and Biology of Insulin and Leptin
Authors: Jeffrey S Flier
Journal: Endocrine Reviews (2018)

Insulin and leptin are critical metabolic hormones that play essential but distinct roles in regulating the physiologic switch between the fed and starved states. The discoveries of insulin and leptin, in 1922 and 1994, respectively, arose out of radically different scientific environments. Despite the dearth of scientific tools available in 1922, insulin's discovery rapidly launched a life-saving therapy for what we now know to be type I diabetes, and continually enhanced insulin therapeutics are now effectively applied to both major forms of this increasingly prevalent disease. In contrast, although the discovery of leptin provided deep insights into the regulation of central nervous system energy balance circuits, as well as an effective therapy for an extremely rare form of obesity, its therapeutic impact beyond that has been surprisingly limited. Despite an enormous accumulated body of information, many important questions remain unanswered about the mechanisms of action and role in disease of both hormones. Additionally, although many decades apart, both discoveries reveal the complexities inherent to scientific collaboration and the assignment of credit, even when the efforts are spectacularly successful.
Influence of the proton pump inhibitor esomeprazole on the bioavailability of regorafenib
Authors: F.M. de Man, K.G.A.M. Hussaarts, M. de With, E. Oomen-De Hoop, H.K. van Halteren, N.C.H.P. van der Burg-De Graauw, F.A.L.M. Eskens, T. van Gelder, R.W.F. van Leeuwen, R.H.J. Mathijssen
Journal: Annals of Oncology (2018)
Phase I/II study of CTLA-4 inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in patients with advanced/refractory solid tumors, with expansion into 2L cervical cancer and solid tumors
Authors: J. Coward, C. Lemech, T. Meniawy, C.D. Dupont, A.M. Gonzalez, M. Lim, D. Savitsky, M. Carini, S. Hu, O. Shebanova, E. Dow, W. Ortuzar, J.S. Buell, R.B. Stein, H. Youssoufian
Journal: Annals of Oncology (2018)
Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development
Authors: Walter Reinisch, Klaus Gottlieb, Jean-Frederic Colombel, Silvio Danese, Remo Panaccione, Julian Panes, Laurent Peyrin-Biroulet, David Rubin, Bruce E. Sands, Stefan Schreiber, Severine Vermeire, Andrew Mulberg, Bill Sandborn
Journal: Clinical Gastroenterology and Hepatology (2018)
Ribociclib (RIB) + fulvestrant (FUL) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-3 biomarker analyses
Authors: P. Neven, K. Petrakova, G.V. Bianchi, L. De La Cruz Merino, G. Jerusalem, J.T. Beck, G.S. Sonke, S. Chia, S. Brucker, Y. Wang, W. He, K. Rodriguez Lorenc, F. Su, S.-A. Im
Journal: Annals of Oncology (2018)
P2.13-42 Osimertinib Treatment for Patients with EGFR exon 20 Insertion Positive Non-Small-Cell Lung Cancer
Authors: B. Van Veggel, A. Van Der Wekken, S. Hashemi, R. Cornelissen, K. Monkhorst, D. Heideman, T. Radonic, E. Schuuring, E. Smit, J. De Langen
Journal: Journal of Thoracic Oncology (2018)
Clinical features and prognosis of eighty-five patients with primary pulmonary lymphoepithelioma-like carcinoma
Authors: Q.Y. Yin, G.Y. Gao, C.Z. Zhou, Z. Zhu, Y.Q. Liu, X.H. Xie, X.Q. Lin, Z.H. Xie, J.X. Zhang, O.Y. Ming, S.Y. Li, R.C. Chen
Journal: Annals of Oncology (2018)
Health policy and system support to optimise community health worker programmes: an abridged WHO guideline
Authors: Giorgio Cometto, Nathan Ford, Jerome Pfaffman-Zambruni, Elie A Akl, Uta Lehmann, Barbara McPake, Madeleine Ballard, Maryse Kok, Maisam Najafizada, Abimbola Olaniran, Onyema Ajuebor, Henry B Perry, Kerry Scott, Bianca Albers, Aron Shlonsky, David Taylor
Journal: The Lancet Global Health (2018)

Optimising community health worker (CHW) programmes requires evidence-based policies on their education, deployment, and management. This guideline aims to inform efforts by planners, policy makers, and managers to improve CHW programmes as part of an integrated approach to strengthen primary health care and health systems. The development of this guideline followed the standard WHO approach to developing global guidelines. We conducted one overview of reviews, 15 systematic reviews (each one on a specific policy question), and a survey of stakeholders' views on the acceptability and feasibility of the interventions under consideration. We assessed the quality of systematic reviews using the AMSTAR tool, and the certainty of the evidence using the GRADE methodology. The overview of reviews identified 122 eligible articles and the systematic reviews identified 137 eligible primary studies. The stakeholder perception survey obtained inputs from 96 respondents. Recommendations were developed in the areas of CHW selection, preservice education, certification, supervision, remuneration and career advancement, planning, community embeddedness, and health system support. These are the first evidence-based global guidelines for health policy and system support to optimise community health worker programmes. Key considerations for implementation include the need to define the role of CHWs in relation to other health workers and plan for the health workforce as a whole rather than by specific occupational groups; appropriately integrate CHW programmes into the general health system and existing community systems; and ensure internal coherence and consistency across different policies and programmes affecting CHWs.
P1.01-64 Impact of STK11 Co-Mutation on Outcomes Following Immunotherapy Among Patients with TP53 and KRAS Mutated Stage IV NSCLC
Authors: M. Marmarelis, E. Bange, S. Bagley, W. Hwang, Y. Yang, J. Thompson, J. Bauml, C. Ciunci, E. Alley, J. Morrissette, R. Cohen, C. Langer, E. Carpenter, C. Aggarwal
Journal: Journal of Thoracic Oncology (2018)
P3.01-01 Prospective Comparison of Four Plasma Testing Platforms for T790M and Effectiveness of Osimertinib in Chinese NSCLC Patients
Authors: Y. Wu, Y. Chen, G. Wu, H. Zhang, Y. Lu, Y. Cheng, Y. Hu, Z. Liang, J. Wang, J. Ying, W. Liu, X. Zhang, Z. Liang
Journal: Journal of Thoracic Oncology (2018)
Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic colorectal cancer (mCRC)
Authors: J. Hays, J. Zhang, J.D. Berlin, M. O'Hara, M.A. Shah, W. Reichmann, W. Senapedis, H. Achour, E. Baloglu, S. Shacham, M. Kauffman
Journal: Annals of Oncology (2018)
Scientists on the Spot: Carol Ann Remme on her research and career
Authors: Anke M Smits, Carol Ann Remme
Journal: Cardiovascular Research (2018)

At present, her research focuses on cardiac arrhythmias and sudden cardiac death (in particular inherited sodium channelopathies), combining clinical data with functional studies in transgenic models and human induced pluripotent stem cell-derived (iPSC) cardiomyocytes.Additional research interests include the identification of novel (genetic) determinants and modifiers of cardiac electrophysiology and arrhythmia risk.She is currently the Incoming Chairperson of the ESC Working Group on Cardiac Cellular Electrophysiology.
Phase III study comparing bevacizumab plus erlotinib (BE) to erlotinib (E) in patients (pts) with untreated NSCLC harboring EGFR mutations: NEJ026
Authors: Y. Kawashima, T. Fukuhara, N. Furuya, H. Saito, K. Watanabe, S. Iwasawa, Y. Tsunezuka, O. Yamaguchi, M. Okada, K. Yoshimori, I. Nakachi, A. Gemma, K. Azuma, K. Hagiwara, T. Nukiwa, S. Morita, K. Kobayashi, M. Maemondo
Journal: Annals of Oncology (2018)
Magnetic Resonance Imaging Is Cost‐Effective for Hepatocellular Carcinoma Surveillance in High‐Risk Patients With Cirrhosis
Authors: Hye‐Lin Kim, Jihyun An, Jae‐A Park, Seung‐Hoo Park, Young‐Suk Lim, Eui‐Kyung Lee
Journal: Hepatology (2018)

Ultrasonography (US) is generally recommended for the surveillance of hepatocellular carcinoma (HCC) in patients at risk. However, in patients with cirrhosis who have sufficiently high HCC incidence, surveillance using magnetic resonance imaging (MRI) with liver-specific contrast showed markedly higher sensitivity in detecting early-stage HCC than US. This study aimed to compare the cost-effectiveness of semiannual surveillance using MRI versus US in patients with compensated cirrhosis and to identify the population that would gain optimal cost-effectiveness through MRI surveillance. We designed a Markov model to compare the expected costs and quality-adjusted life-years (QALYs), between MRI and US, with a 20-year time horizon, from the health care system perspective. The starting age of the cohort was 50 years, and 71% had hepatitis B virus-associated cirrhosis. The cycle length was 6 months. Transition probabilities and costs were obtained mainly from a prospective cohort study (the PRIUS study, NCT01446666). Cost and effectiveness were discounted at 5%. An incremental cost-effectiveness ratio (ICER) was calculated and tested using sensitivity analyses. The cost-effectiveness analysis indicated that the use of MRI incurred $5,562 incremental costs, 0.384 incremental life-years (LYs), and 0.221 incremental QALYs compared to US. The annual HCC incidence was the most influential factor on the ICER. The ICERs were $14,474/LY and $25,202/QALY at an annual HCC incidence of 3%. When the HCC incidence rate was >1.81%, the ICER was below $50,000/QALY. With increased HCC incidence, MRI surveillance was acceptable as a cost-effective option, even with an increased MRI/US cost ratio. Conclusion: Semiannual surveillance using MRI with liver-specific contrast may be more cost-effective than US in patients with virus-associated compensated cirrhosis at sufficiently high HCC risk despite the higher test cost of MRI.
Systematic review of musculoskeletal injuries in professional golfers
Authors: Patrick G Robinson, Iain R Murray, Andrew D Duckworth, Roger Hawkes, Danny Glover, Nigel R Tilley, Rob Hillman, Christopher W Oliver, Andrew D Murray
Journal: British Journal of Sports Medicine (2018)

Objective The distribution of injuries affecting professional golfers is yet to be fully understood. We performed a systematic review of the clinical literature to establish the epidemiology of musculoskeletal injuries affecting professional golfers. Design Systematic review. Data sources Searched databases in July 2018 were PubMed, SPORTDiscus and Embase. Eligibility criteria Published observational research articles relating to the incidence or prevalence of musculoskeletal injuries in professional golfers, which were written in the English language and not restricted by age or gender. Results Of the 1863 studies identified on the initial search, 5 studies were found to satisfy the inclusion criteria for analysis. The mean age of the golfers in these studies was 34.8 (±3.6) years. The gender of patients in included studies compromised 72% males and 28% females. Four studies reported that lumbar spine injuries were the most common (range 22%–34%). Excluding injuries to the spine (lumbar, thoracic and cervical), the hand/wrist was the next most common region of injury (range 6%–37%). The quality of the studies was relatively poor with no study satisfying &gt;50% of the quality assessment tool questions and only one study giving a clear definition of how they defined injury. Conclusion There is a paucity of well-designed epidemiological studies evaluating musculoskeletal injuries affecting professional golfers. Injuries to the spine are the most frequently affected region, followed by the hand/wrist. This study has identified targeted areas of future research that aims to improve the management of injuries among professional golfers.
Can preoperative diagnosis select therapeutic target of neoadjuvant chemotherapy for gastric cancer?
Authors: K. Hara, T. Hayashi, Y. Shimoda, M. Nakazono, S. Nagasawa, Y. Kumazu, T. Yamada, Y. Rino, M. Masuda, T. Ogata, T. Oshima, T. Yoshikawa
Journal: Annals of Oncology (2018)
Abstract 18593: Implantable Cardioverter-defibrillator for Sudden Cardiac Death Prevention in Korea: Results From a Nationwide Population-based Study
Authors: Seung-Young Roh, Jong-Il Choi, Eun Young Cho, Yun Gi Kim, Suk-kyu Oh, Hee-Soon Park, Kwang No Lee, Jaemin Shim, Young-Hoon Kim
Journal: Circulation (2017)

Introduction: Benefits of implantable cardioverter-defibrillator (ICD) in prevention of sudden cardiac arrest (SCA) are proven. However, epidemiology and indication of ICD in real world remains largely unknown. Hypothesis: Real-world implantation of ICDs may differ from that ideal indication. Method: The patients who underwent ICD implantation were identified using the Health Insurance Review and Assessment Service database between 2007 and 2015. Among the nonischemic causes, inherited arrhythmia as an indication of ICD implantation was estimated excluding all other cardiomyopathy and heart failure. Results: Total 4620 ICD implantation was performed during 9 years in Korea. ICD implantation for primary prevention was 1496 (32.4%) and 3124 (67.6%) was for secondary prevention. Implantation number and proportion of primary prevention were increased from 236 (primary prevention 7.2%) in 2007 to 1023 (primary prevention 43.1%) in 2015. Primary prevention was more frequently performed in old (≥40 years old) co...
Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort in a phase I study
Authors: M.J. Pishvaian, G.J. Weiss, G.S. Falchook, N. Yee, M. Gil-Martin, S. Shahda, V. Moreno, I. Brana, M. Crittenden, S. Formenti, R. Al-Rajabi, K.P. Papadopoulos, E. Stankevich, M. Feng, J. Li, M. Mathias, G. Kroog, I. Lowy, M.G. Fury
Journal: Annals of Oncology (2018)
P1.01-03 Effect of Prophylactic Cranial Irradiation on Cognitive Function and QoL in NSCLC Patients at High Risk of Brain Metastases
Authors: A. Gonzalez-Ling, F. Maldonado, M. Salinas Padilla, M. Arguelles, L. Ramírez-Tirado, Z. Zatarain-Barrón, F. Barron, L.A. Cabrera-Miranda, D. Flores, A. Cardona, O. Arrieta
Journal: Journal of Thoracic Oncology (2018)